Autoimmune/Cholestatic/Biliary Diseases

Top Story

PBC recurrence after liver transplantation decreases survival rates

January 7, 2019

ArTara advances trial of intestinal failure-associated liver disease therapy

January 2, 2019
ArTara Therapeutics has completed an end-of-phase 2 meeting with the FDA to discuss a phase 3 study of intravenous choline chloride substrate replacement for patients…
In the Journals

Autoimmune hepatitis lowers quality of life regardless of remission

December 28, 2018
Patients with autoimmune hepatitis reported lower health-related quality of life compared with the general population, often related to corticosteroid use independent of…

Albireo receives European orphan designation for biliary atresia therapy

December 27, 2018
Albireo Pharma received European Commission orphan designation for its lead product candidate A4250, an ileal bile acid transporter inhibitor for the treatment of…
More Headlines »

Cirrhosis and Hepatic Encephalopathy – Managing Their Consequences and Complications

This activity is supported by an educational grant from Salix Pharmaceuticals, a division of Valeant Pharmaceuticals North America LLC.

Cirrhosis, or advanced fibrosis of the liver, can lead to serious health sequelae or death. However, substantial…
More »
GI Bookshelf

Question 28: I Have A Patient With Biliary-Type Pain, But No Other Evidence Of Bile Duct Disease (Normal Diameter Duct On Ultrasound, Normal Liver Function Tests). How Should Such A Patient Be Managed?

From Curbside Consultation in Endoscopy: 49 Clinical Questions, Second Edition
More »
Meeting News

VIDEO: GS-9674 demonstrates safety, efficacy for PSC

November 29, 2018
More »